This session will review a number of clinically relevant trials/topics recently presented at the American College of Cardiology Scientific Sessions in March 2017, including updates in the management of patients with hypercholesterolemia, heart failure, valvular heart disease, arrhythmias, and more.

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.

In this case presentation, Dr. Lee shares strategies for designing basal insulin regimens considering patient comorbidities and socioeconomic factors, highlights the differences between conventional and newer basal insulins, and describes how to appropriately initiate and dose newer basal insulin products in patients with type 2 diabetes.

Join us as we discuss key points from the 2019 update to the American Diabetes Association and the European Association for the Study of Diabetes consensus report. This update is now reflected in the American Diabetes Association's Standards of Medical Care—2020.

Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients.

Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients.

Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients.

In this expert perspective, Dr. Richard E. Pratley shares strategies for designing insulin regimens that are individualized based upon patient-specific factors. He will also describe the differences between conventional basal insulin products and new-generation basal insulin products, and how to appropriately initiate and titrate newer basal insulin products.

This talk will provide an opportunity for the learner to (anonymously) test his/her knowledge in the management of people with type 2 diabetes using cases and an ARS. The cases will also be used to illustrate the pathophysiology of type 2 diabetes and provide an opportunity for developing a practical approach to treating people with type 2 diabetes, utilizing the commonest and newest medications available. The cases will also help the learners use medications safely and understand advantages and disadvantages, and common side effects of each class of medication. Finally a practical approach to the initiation and intensification of basal insulin will be covered.

In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).

This series of interactive cases will provide an opportunity for the learner to increase their knowledge in the management of people with type 2 diabetes on insulin therapy. The cases will illustrate expert guidelines and general strategies around use of insulin and combinations of injectables for type 2 diabetes, including a practical approach to the initiation and intensification of basal insulin. You will learn the advantages and disadvantages of combination injectable medications as well as how to use them safely and appropriately.

Diabetic kidney disease is expected to surpass all other diabetes-related complications in morbidity and mortality. In this session, faculty will review current data on the renoprotective properties of SGLT2 inhibitors and explain the guideline recommendations for their use in patients with type 2 diabetes and kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/4/2019, and they are subject to change as new information is published.